Monday, September 06, 2010
bloeddruk perindopril
Abstract and Introduction
Abstract
The renin-angiotensin-aldosterone system (RAAS) plays a major role in blood pressure regulation and is thus an important therapeutic target in the management of hypertension. Angiotensin receptor blockers (ARBs), which interrupt RAAS overactivity by blocking a specific receptor that mediates the pathogenic activity of angiotensin II, represent a major addition to the clinician's armamentarium for the management of hypertension. A solid body of clinical evidence demonstrates that ARBs are effective in the management of hypertension as monotherapy or in combination with other agents. Although comparable to angiotensin-converting enzyme inhibitors and other major classes of antihypertensive agents in the treatment of hypertension, the favorable tolerability profile of ARBs make them an attractive alternative for many patients. Recent evidence suggests that treatment persistence with ARB therapy during a 12-month period is typically higher than with other antihypertensive classes, a finding perhaps driven by fewer treatment-limiting side effects. The combination of clinical efficacy and tolerability should render ARBs as a major treatment alternative for hypertension.
Introduction
Because of its central role in the pathogenesis of cardiovascular disease, the renin-angiotensin-aldosterone system (RAAS) has been a subject of intense research for the past 40 years and an important target for pharmacological intervention in the management of hypertension. This paper provides a brief overview of RAAS function and a review of clinical data related to the use of angiotensin receptor blockers (ARBs) to treat hypertension.
Abstract
The renin-angiotensin-aldosterone system (RAAS) plays a major role in blood pressure regulation and is thus an important therapeutic target in the management of hypertension. Angiotensin receptor blockers (ARBs), which interrupt RAAS overactivity by blocking a specific receptor that mediates the pathogenic activity of angiotensin II, represent a major addition to the clinician's armamentarium for the management of hypertension. A solid body of clinical evidence demonstrates that ARBs are effective in the management of hypertension as monotherapy or in combination with other agents. Although comparable to angiotensin-converting enzyme inhibitors and other major classes of antihypertensive agents in the treatment of hypertension, the favorable tolerability profile of ARBs make them an attractive alternative for many patients. Recent evidence suggests that treatment persistence with ARB therapy during a 12-month period is typically higher than with other antihypertensive classes, a finding perhaps driven by fewer treatment-limiting side effects. The combination of clinical efficacy and tolerability should render ARBs as a major treatment alternative for hypertension.
Introduction
Because of its central role in the pathogenesis of cardiovascular disease, the renin-angiotensin-aldosterone system (RAAS) has been a subject of intense research for the past 40 years and an important target for pharmacological intervention in the management of hypertension. This paper provides a brief overview of RAAS function and a review of clinical data related to the use of angiotensin receptor blockers (ARBs) to treat hypertension.
# posted by roodbont @ 6:11 AM 
